BofA Maintains an Underperform Rating on Hims & Hers Health, Inc. (HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) is among the 7 Best Beauty Stocks to Buy Right Now.

TheFly reported on January 8, 2026, that BofA reduced the price target for Hims & Hers Health, Inc. (NYSE:HIMS) to $29 from $32. It retained an Underperform rating on the stock. The firm claims that the consensus expectations for sales and EBITDA margins in 2026 are excessively high. It notes that 2026 will be Hims & Hers’ “big investment year” and that projections for an increase in EBITDA margin seem excessively optimistic. BofA expects negative earnings revisions in the upcoming months and risks of downside to 2026 revenue and EBITDA margins.

Citi reported on January 5, 2026, that the corporation was once more left off of Novo Nordisk’s partner list for the Wegovy weight loss pill’s U.S. launch. It also includes CVS Health, Costco, LifeMD, and GoodRx. This exclusion is possibly due to differences between Novo and the company’s compounded semaglutide strategy. In 2026, Citi forecasts that the Wegovy launch will put pressure on Hims & Hers Health, Inc. (NYSE:HIMS) GLP-1 business. The firm remains to have a $30 price target and a Sell rating. In the premarket, the stock was trading at $33.85, up $0.44.

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the top telehealth firms in the United States.

While we acknowledge the potential of HIMS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.